Flamel Technologies Announces Results of Annual Meeting and Election of Stephen H. Willard Chairman
25 6월 2012 - 9:30PM
Marketwired
Flamel Technologies S.A. (NASDAQ: FLML) today announced voting
results from the Company's annual ordinary and extraordinary
meeting held on June 22, 2012. Approximately 98 percent of
outstanding shares were represented at the meeting. The director
nominees Dr. Catherine Bréchignac, Mr. Guillaume Cerutti, Dr.
Francis J.T. Fildes, Ambassador Craig Stapleton, Mr. Elie Vannier,
and Mr. Stephen H. Willard were each reelected to Flamel's board of
directors for a further one-year term. Mr. Michael S. Anderson, a
new director nominee, was also elected. Each director received at
least 97 percent of the votes cast.
In addition, the board of directors also appointed former Flamel
Chief Executive Officer, Stephen H. Willard, as Chairman of the
Board.
"Stephen has played an instrumental role in the evolution of
Flamel's business over the years, and I am delighted that the
company will be able to continue to benefit from his leadership and
guidance," said Michael S. Anderson, Chief Executive Officer.
"I am privileged to have the opportunity to serve Flamel as
Chairman and am confident Mike and his team are focused on
executing a more vertically integrated strategy that should enhance
value for Flamel's shareholders," said Mr. Willard.
Stockholders also approved a management proposal recommending
the issuance of a total of 3.3 million stock warrants to Éclat
Holdings, LLC related to the acquisition announced on March 14,
2012 at prices of $7.44 and $11.00. Approximately 97 percent of
outstanding shares were cast "For" the proposal.
Each additional resolution proposed favorably by management at
the meeting was approved overwhelmingly.
Flamel also announced the appointment of Steven Lisi as Senior
Vice President of Business and Corporate Development, effective
June 25, 2012. Mr. Lisi joins Flamel from Deerfield Capital
Management, where he helped manage the firm's healthcare portfolio
and worked on numerous strategic transactions in the healthcare
space.
"We are delighted that Steve has agreed to join Flamel," said
Mr. Anderson. "His extensive experience with strategic transactions
in the pharmaceutical space and in-depth knowledge across a variety
of therapeutic areas will be an invaluable asset as we redouble our
focus on growth and execution."
About Flamel Technologies Flamel
Technologies SA (NASDAQ: FLML) is a leading drug delivery company
focused on the goal of developing safer, more efficacious
formulations of drugs that address unmet medical needs. Its product
development pipeline includes biological and chemical drugs
formulated with the Medusa® and Micropump® proprietary platforms.
Several Medusa-based products are at various clinical stages of
development; Medusa's lead internal product candidate IFN-alpha XL
(long-acting interferon alpha-2b) is being evaluated a Phase 2a
trial in HCV patients. The Company has developed approved products
and manufactures Micropump-based microparticles under FDA-audited
GMP guidelines. Flamel Technologies has collaborations with a
number of leading pharmaceutical and biotechnology companies,
including GlaxoSmithKline (Coreg CR®, carvedilol phosphate) and
Merck Serono (long-acting interferon beta-1a). Flamel recently
acquired Éclat Pharmaceuticals, a St. Louis, Missouri-based
specialty pharmaceutical company focused on developing and
commercializing niche brands and generic products. Additional
information can be found at www.flamel.com
This document contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including certain plans, expectations, goals and projections
regarding financial results, product developments and technology
platforms. All statements that are not clearly historical in nature
are forward-looking, and the words "anticipate," "assume,"
"believe," "expect," "estimate," "plan," "will," and similar
expressions are generally intended to identify forward-looking
statements. All forward-looking statements involve risks,
uncertainties and contingencies, many of which are beyond our
control that could cause actual results to differ materially from
those contemplated in such forward-looking statements. These risks
include risks that the acquisition of Éclat Pharmaceuticals will
not be successful, the expected timing of the filing of our first
New Drug Application (NDA) with the FDA may be delayed, the
identified opportunities will not result in shorter-term, high
value results, clinical trial results will not be positive or that
our partners may decide not to move forward, management transition
to a new chief executive officer may be disruptive or not succeed
as planned, products in the development stage may not achieve
scientific objectives or milestones or meet stringent regulatory
requirements, products in development may not achieve market
acceptance, competitive products and pricing may hinder our
commercial opportunities we may not be successful in identifying
and pursuing opportunities to develop our own product portfolio
using Flamel's technology, and the risks associated with our
reliance on outside parties and key strategic alliances. These and
other risks are described more fully in Flamel's Annual Report on
Form 20-F for the year ended December 31, 2011 that has been filed
with the Securities and Exchange Commission (SEC). All
forward-looking statements included in this release are based on
information available at the time of the release. We undertake no
obligation to update or alter our forward-looking statements as a
result of new information, future events or otherwise.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024